rewirebio.iobenchmarks
Dataset subset

Immunotherapy arms of six held-out trials with evaluable response

Immunotherapy-treated patients with a designated pretreatment RNA sample and evaluable RECIST response in OAK, POPLAR, IMvigor210, IMmotion150, IMmotion151 and IMbrave150.

Evaluation results

10 evaluations · 10 results. Different protocols are not a single leaderboard.

Filter evaluations

Applied filters: All linked evaluations

Exact evaluated configurations and original reported results
Tested configurationProtocol and datasetFindingEvidence and details
Configuration: BulkFormer 147M (Ladon report comparator)Protocol: Held-out trials, immunotherapy response AUROC, equal mean over six trials
Dataset subset: Immunotherapy arms of six held-out trials with evaluable response
0.629 AUROC (AUROC for RECIST complete or partial response against other evaluable responses, immunotherapy arms, equal mean over six held-out trials)
unitless · higher

Uncertainty: Not reported by the source: Per-trial dots and a bar only; no interval is printed.

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

BulkFormer, held-out trials immunotherapy response AUROC

ladon-20261115-protocol-trials-response-auroc

Aggregation: Not reported

Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) · Figure 6 (page 10), row 'BulkFormer', bar label
Configuration: BulkRNABert, published Hugging Face checkpoint (Ladon report comparator)Protocol: Held-out trials, immunotherapy response AUROC, equal mean over six trials
Dataset subset: Immunotherapy arms of six held-out trials with evaluable response
0.612 AUROC (AUROC for RECIST complete or partial response against other evaluable responses, immunotherapy arms, equal mean over six held-out trials)
unitless · higher

Uncertainty: Not reported by the source: Per-trial dots and a bar only; no interval is printed.

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

BulkRNABert, held-out trials immunotherapy response AUROC

ladon-20261115-protocol-trials-response-auroc

Aggregation: Not reported

Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) · Figure 6 (page 10), row 'BulkRNABert', bar label
Configuration: Clinical covariates encoded by BMRetriever-7B (Ladon report baseline)Protocol: Held-out trials, immunotherapy response AUROC, equal mean over six trials
Dataset subset: Immunotherapy arms of six held-out trials with evaluable response
0.515 AUROC (AUROC for RECIST complete or partial response against other evaluable responses, immunotherapy arms, equal mean over six held-out trials)
unitless · higher

Uncertainty: Not reported by the source: Per-trial dots and a bar only; no interval is printed.

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Clinical covariates (BMRetriever), held-out trials immunotherapy response AUROC

ladon-20261115-protocol-trials-response-auroc

Aggregation: Not reported

Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) · Figure 6 (page 10), row 'Clinical covariates (BMRetriever)', bar label
Method: Differential gene expression signature (Ladon report)Protocol: Held-out trials, immunotherapy response AUROC, equal mean over six trials
Dataset subset: Immunotherapy arms of six held-out trials with evaluable response
0.633 AUROC (AUROC for RECIST complete or partial response against other evaluable responses, immunotherapy arms, equal mean over six held-out trials)
unitless · higher

Uncertainty: Not reported by the source: Per-trial dots and a bar only; no interval is printed.

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Differential gene expression, held-out trials immunotherapy response AUROC

ladon-20261115-protocol-trials-response-auroc

Aggregation: Not reported

Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) · Figure 6 (page 10), row 'Differential gene expression', bar label
Method: Gene TPM features with academic-only context (Ladon report)Protocol: Held-out trials, immunotherapy response AUROC, equal mean over six trials
Dataset subset: Immunotherapy arms of six held-out trials with evaluable response
0.613 AUROC (AUROC for RECIST complete or partial response against other evaluable responses, immunotherapy arms, equal mean over six held-out trials)
unitless · higher

Uncertainty: Not reported by the source: Per-trial dots and a bar only; no interval is printed.

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Gene TPM, held-out trials immunotherapy response AUROC

ladon-20261115-protocol-trials-response-auroc

Aggregation: Not reported

Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) · Figure 6 (page 10), row 'Gene TPM', bar label
Method: IMPRESProtocol: Held-out trials, immunotherapy response AUROC, equal mean over six trials
Dataset subset: Immunotherapy arms of six held-out trials with evaluable response
0.505 AUROC (AUROC for RECIST complete or partial response against other evaluable responses, immunotherapy arms, equal mean over six held-out trials)
unitless · higher

Uncertainty: Not reported by the source: Per-trial dots and a bar only; no interval is printed.

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

IMPRES, held-out trials immunotherapy response AUROC

ladon-20261115-protocol-trials-response-auroc

Aggregation: Not reported

Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) · Figure 6 (page 10), row 'IMPRES', bar label
Configuration: Ladon, response mid-trained, PCA 128 + TabICL v2 (held-out trial response)Protocol: Held-out trials, immunotherapy response AUROC, equal mean over six trials
Dataset subset: Immunotherapy arms of six held-out trials with evaluable response
0.673 AUROC (AUROC for RECIST complete or partial response against other evaluable responses, immunotherapy arms, equal mean over six held-out trials)
unitless · higher

Uncertainty: Not reported by the source: Per-trial dots and a bar only; no interval is printed.

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Ladon, held-out trials immunotherapy response AUROC

ladon-20261115-protocol-trials-response-auroc

Aggregation: Not reported

Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) · Figure 6 (page 10), row 'Ladon', bar label
Method: PD-L1 mRNA (CD274 expression)Protocol: Held-out trials, immunotherapy response AUROC, equal mean over six trials
Dataset subset: Immunotherapy arms of six held-out trials with evaluable response
0.597 AUROC (AUROC for RECIST complete or partial response against other evaluable responses, immunotherapy arms, equal mean over six held-out trials)
unitless · higher

Uncertainty: Not reported by the source: Per-trial dots and a bar only; no interval is printed.

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

PD-L1 mRNA, held-out trials immunotherapy response AUROC

ladon-20261115-protocol-trials-response-auroc

Aggregation: Not reported

Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) · Figure 6 (page 10), row 'PD-L1 mRNA', bar label
Method: T-effector / IFN-gamma signatureProtocol: Held-out trials, immunotherapy response AUROC, equal mean over six trials
Dataset subset: Immunotherapy arms of six held-out trials with evaluable response
0.628 AUROC (AUROC for RECIST complete or partial response against other evaluable responses, immunotherapy arms, equal mean over six held-out trials)
unitless · higher

Uncertainty: Not reported by the source: Per-trial dots and a bar only; no interval is printed.

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

T-effector / IFN-γ, held-out trials immunotherapy response AUROC

ladon-20261115-protocol-trials-response-auroc

Aggregation: Not reported

Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) · Figure 6 (page 10), row 'T-effector / IFN-γ', bar label
Method: TIDEProtocol: Held-out trials, immunotherapy response AUROC, equal mean over six trials
Dataset subset: Immunotherapy arms of six held-out trials with evaluable response
0.492 AUROC (AUROC for RECIST complete or partial response against other evaluable responses, immunotherapy arms, equal mean over six held-out trials)
unitless · higher

Uncertainty: Not reported by the source: Per-trial dots and a bar only; no interval is printed.

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

TIDE, held-out trials immunotherapy response AUROC

ladon-20261115-protocol-trials-response-auroc

Aggregation: Not reported

Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) · Figure 6 (page 10), row 'TIDE', bar label

Source checking is not independent reproduction. Release 2026-11-21-c8bea25e5abb.

Research readiness

0 of 4 readiness checks met. These checks assess whether the evidence supports a reproducible investigation; a source-checked score alone does not meet them.

Readiness checks, gaps and artifacts

Release 2026-11-21-c8bea25e5abb · Evidence verified: Not verified

Evidence incomplete

Replay metrics

Exact outcomes, predictions, identifiers and evaluator are connected.

Missing or unresolved evidence

  • No verified artifact manifest is linked to this exact record.
  • File checksums match the recorded files: not yet verified
  • Predictions are matched to the right samples: not yet verified
  • Score meaning and direction are confirmed: not yet verified
  • Metrics are recomputed from the saved predictions: not yet verified

Verified: Not verified

Evidence incomplete

Investigate discrepancies

Replay evidence includes annotations and an assessment of dependence. Unknown independence permits descriptive analysis only.

Missing or unresolved evidence

  • No verified artifact manifest is linked to this exact record.
  • File checksums match the recorded files: not yet verified
  • Predictions are matched to the right samples: not yet verified
  • Score meaning and direction are confirmed: not yet verified
  • Metrics are recomputed from the saved predictions: not yet verified
  • Sample annotations are recorded: not yet verified
  • Dependence between samples is assessed: not yet verified

Verified: Not verified

Evidence incomplete

Run locally

A pinned recipe describes the inputs, environment and resource requirements.

Missing or unresolved evidence

  • No verified artifact manifest is linked to this exact record.
  • File checksums match the recorded files: not yet verified
  • Predictions are matched to the right samples: not yet verified
  • Score meaning and direction are confirmed: not yet verified
  • A pinned run recipe exists: not yet verified
  • Compute requirements are estimated: not yet verified

Verified: Not verified

Evidence incomplete

Validate independently

Separate data and exposure records support an independent test.

Missing or unresolved evidence

  • No verified artifact manifest is linked to this exact record.
  • File checksums match the recorded files: not yet verified
  • Predictions are matched to the right samples: not yet verified
  • Score meaning and direction are confirmed: not yet verified
  • Independent validation data exist: not yet verified
  • Overlap with training data is checked: not yet verified

Verified: Not verified

Readiness describes the evidence in this release. Availability on your computer is checked separately when an investigation runs. Existing data exposure can prevent independent validation even when files are available.

Artifacts and reproduction

No verified artifact manifest is connected to this record yet. The gaps above identify what is needed before analysis can begin.

Subset and evaluation context

This record describes a particular subset or cohort used in an evaluation. Its results do not describe the full dataset.

Evidence

Source checking verifies the cited claim or transcription. It does not establish independent reproduction.

Evidence table

Inspect claims, sources and review details

Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.

One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.

9 evidence rows matching the loaded filters

Claims, original sources and review scope · Release 2026-11-21-c8bea25e5abb
Property and statementOriginal source and locationReview and provenance
Limitations
1 values
  • Patient and responder counts per trial are not printed.
Context-only references
Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF)

Original source ↗

Page 15 trial table and eligibility paragraph

Version: Zenodo record 24157116 (version DOI 10.5281/zenodo.24157116; concept DOI 10.5281/zenodo.24157115), file Ladon-An-RNA-Foundation-Model-for-Predicting-Patient-Outcomes.pdf, 47 pages, dated 12 November 2026
Retrieved: 2026-11-15T20:29:10Z

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.limitations

Source artifact SHA-256: 64edf7c3c956c50a65aa01a0dcaa13f0cfef28ab4373ecfd50c431e67143893c

Hash scope: Hash scope not separately documented; inspect source record

Source dataset
ladon-20261115-data-held-out-trials
Context-only references
Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF)

Original source ↗

Page 15 trial table and eligibility paragraph

Version: Zenodo record 24157116 (version DOI 10.5281/zenodo.24157116; concept DOI 10.5281/zenodo.24157115), file Ladon-An-RNA-Foundation-Model-for-Predicting-Patient-Outcomes.pdf, 47 pages, dated 12 November 2026
Retrieved: 2026-11-15T20:29:10Z

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.source_dataset

Source artifact SHA-256: 64edf7c3c956c50a65aa01a0dcaa13f0cfef28ab4373ecfd50c431e67143893c

Hash scope: Hash scope not separately documented; inspect source record

Source location
Page 15 trial table and eligibility paragraph
Context-only references
Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF)

Original source ↗

Page 15 trial table and eligibility paragraph

Version: Zenodo record 24157116 (version DOI 10.5281/zenodo.24157116; concept DOI 10.5281/zenodo.24157115), file Ladon-An-RNA-Foundation-Model-for-Predicting-Patient-Outcomes.pdf, 47 pages, dated 12 November 2026
Retrieved: 2026-11-15T20:29:10Z

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.source_locator

Source artifact SHA-256: 64edf7c3c956c50a65aa01a0dcaa13f0cfef28ab4373ecfd50c431e67143893c

Hash scope: Hash scope not separately documented; inspect source record

Split
Evaluation only
Context-only references
Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF)

Original source ↗

Page 15 trial table and eligibility paragraph

Version: Zenodo record 24157116 (version DOI 10.5281/zenodo.24157116; concept DOI 10.5281/zenodo.24157115), file Ladon-An-RNA-Foundation-Model-for-Predicting-Patient-Outcomes.pdf, 47 pages, dated 12 November 2026
Retrieved: 2026-11-15T20:29:10Z

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.split

Source artifact SHA-256: 64edf7c3c956c50a65aa01a0dcaa13f0cfef28ab4373ecfd50c431e67143893c

Hash scope: Hash scope not separately documented; inspect source record

Subset scope
Immunotherapy arms only; responders are complete or partial RECIST responses
Context-only references
Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF)

Original source ↗

Page 15 trial table and eligibility paragraph

Version: Zenodo record 24157116 (version DOI 10.5281/zenodo.24157116; concept DOI 10.5281/zenodo.24157115), file Ladon-An-RNA-Foundation-Model-for-Predicting-Patient-Outcomes.pdf, 47 pages, dated 12 November 2026
Retrieved: 2026-11-15T20:29:10Z

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.subset_scope

Source artifact SHA-256: 64edf7c3c956c50a65aa01a0dcaa13f0cfef28ab4373ecfd50c431e67143893c

Hash scope: Hash scope not separately documented; inspect source record

Version
As described in the Ladon technical report
Context-only references
Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF)

Original source ↗

Page 15 trial table and eligibility paragraph

Version: Zenodo record 24157116 (version DOI 10.5281/zenodo.24157116; concept DOI 10.5281/zenodo.24157115), file Ladon-An-RNA-Foundation-Model-for-Predicting-Patient-Outcomes.pdf, 47 pages, dated 12 November 2026
Retrieved: 2026-11-15T20:29:10Z

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.version

Source artifact SHA-256: 64edf7c3c956c50a65aa01a0dcaa13f0cfef28ab4373ecfd50c431e67143893c

Hash scope: Hash scope not separately documented; inspect source record

Description
Immunotherapy-treated patients with a designated pretreatment RNA sample and evaluable RECIST response in OAK, POPLAR, IMvigor210, IMmotion150, IMmotion151 and IMbrave150.
Context-only references
Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF)

Original source ↗

Page 15 trial table and eligibility paragraph

Version: Zenodo record 24157116 (version DOI 10.5281/zenodo.24157116; concept DOI 10.5281/zenodo.24157115), file Ladon-An-RNA-Foundation-Model-for-Predicting-Patient-Outcomes.pdf, 47 pages, dated 12 November 2026
Retrieved: 2026-11-15T20:29:10Z

not individually reviewed

No individual claim review recorded

Audit details

Field: description

Source artifact SHA-256: 64edf7c3c956c50a65aa01a0dcaa13f0cfef28ab4373ecfd50c431e67143893c

Hash scope: Hash scope not separately documented; inspect source record

Relationship: used in
ladon-20261115-protocol-trials-response-auroc
Context-only references
Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF)

Original source ↗

Page 15 trial table and eligibility paragraph

Version: Zenodo record 24157116 (version DOI 10.5281/zenodo.24157116; concept DOI 10.5281/zenodo.24157115), file Ladon-An-RNA-Foundation-Model-for-Predicting-Patient-Outcomes.pdf, 47 pages, dated 12 November 2026
Retrieved: 2026-11-15T20:29:10Z

not individually reviewed

No individual claim review recorded

Audit details

Field: links:used_in:ladon-20261115-protocol-trials-response-auroc

Source artifact SHA-256: 64edf7c3c956c50a65aa01a0dcaa13f0cfef28ab4373ecfd50c431e67143893c

Hash scope: Hash scope not separately documented; inspect source record

Name
Immunotherapy arms of six held-out trials with evaluable response
Context-only references
Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF)

Original source ↗

Page 15 trial table and eligibility paragraph

Version: Zenodo record 24157116 (version DOI 10.5281/zenodo.24157116; concept DOI 10.5281/zenodo.24157115), file Ladon-An-RNA-Foundation-Model-for-Predicting-Patient-Outcomes.pdf, 47 pages, dated 12 November 2026
Retrieved: 2026-11-15T20:29:10Z

not individually reviewed

No individual claim review recorded

Audit details

Field: name

Source artifact SHA-256: 64edf7c3c956c50a65aa01a0dcaa13f0cfef28ab4373ecfd50c431e67143893c

Hash scope: Hash scope not separately documented; inspect source record

Sources and history

Release 2026-11-21-c8bea25e5abb · Record review: source checked

1 source record and release historyDownload this release (gzip)
Technical metadata and record identifiers

Technical metadata for this record is tracked under stable ID ladon-20261115-data-trials-response-six.

Source locator: Page 15 trial table and eligibility paragraph

Related records

Suggest a correction